NEULANDLAB23,800.00

Neuland Laboratories Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABLAURUSLABSNHNATCOPHARMLALPATHLABSAILIFECOHANCEASTERDMMcap ₹30,703 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation59.765.591.7
+ Finance Costs14.08.323.9
+ Interest Income-8.2-10.6-10.1
+ Fair Value (Gains) / Losses0.0-7.70.0
+ Unrealised FX (Gain) / Loss-3.5-0.21.3
+ Other Non-cash Items0.2-67.4-4.3
Changes in Working Capital
+ Inventories-71.2-35.3-124.5
+ Trade Receivables — Current-8.754.9-224.2
+ Other Financial Assets — Current4.5-1.9-0.7
+ Other Financial Assets — Non-current-1.22.5-7.2
+ Other Current Assets-23.98.4-2.9
+ Other Non-current Assets1.50.00.1
+ Other Bank Balances0.00.0-0.0
+ Trade Payables — Current20.358.816.1
+ Other Financial Liabilities — Current41.9-22.919.1
+ Other Current Liabilities-52.0-6.2173.9
+ Other Non-current Liabilities-0.00.00.0
+ Provisions — Current0.1-0.50.2
+ Provisions — Non-current-2.10.08.7
Cash from Operating Activities
Profit Before Tax (per I/S)401.4346.3489.0669.3
+ Total Adjustments (incl. Working Capital)-28.745.8-38.8
Cash from Operations (pre-tax)372.8392.1450.2
+ Income Taxes Paid111.674.7103.5
Cash from Operating Activities261.2317.4346.7
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)141.5206.5390.2
+ Acq of Intangible Assets2.20.05.9
+ Disp of Fixed Assets1.31.20.9
+ Acq of Intangibles under Development0.00.01.1
+ Disp of Investment Property0.095.40.0
+ Acq of Other Long-term Assets0.00.0150.0
+ Disp of Other Long-term Assets0.00.0265.2
+ Interest Received — Investing7.99.38.6
+ Other Inflows / (Outflows) — Investing-15.2-197.6-151.4
Cash from Investing Activities-149.7-298.2-423.7
Cash from Financing Activities
+ Proceeds from Borrowings8.894.8105.6
+ Repayment of Borrowings48.339.444.7
+ Payment of Lease Liabilities3.65.47.5
+ Interest Paid13.47.017.0
+ Dividends Paid12.818.015.4
Cash from Financing Activities-69.325.021.0
Net Changes in Cash (pre-FX)42.244.2-56.1
+ Effect of FX Rate Changes on Cash0.00.20.8
Net Changes in Cash42.244.4-55.3
Closing Cash87.676.7
Reference Items
EBITDA462.6323.3574.5762.9
EBITDA Margin %29.6821.8928.4032.17
Free Cash Flow (CFO − Capex)117.5110.9-49.4-49.4
Free Cash Flow to Equity157.4-5.8
Free Cash Flow per Basic Share91.0985.98-38.27-38.27
Cash Flow to Net Income0.871.220.95
Cash Paid for Taxes111.674.7103.5
Cash Paid for Interest13.47.017.0
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.